Industries · Dermatology & Cosmetics
From ex vivo explants to cell culture, OMICS4 runs the molecular evidence behind efficacy claims and mechanism-of-action studies, in-house and with our dermo-cosmetic partners.
Platforms used in this field
Overview
OMICS4 runs the bench work behind dermo-cosmetic studies: ex vivo explants sequenced, skin microbiome profiled, low-biomass material handled without losing the signal. Primary data comes back quality-controlled, iteration after iteration, on the same protocol.
Platforms
Protocols tuned for low-input material.
Sequencing and targeted quantification on the same material.
Vesicle isolation and cargo profiling from culture supernatant.
Ex vivo skin explants, biopsies, swabs, tape strips and culture supernatant. Low-biomass sampling is where a standard extraction loses the signal, so the protocol is chosen by matrix. Collection and storage protocols, and the RNA criteria that apply after extraction, are published per sample type.
A QC report for every sample. Demultiplexed FASTQ with run-level QC metrics for the sequencing services. Result tables for PCR work. Turnaround published per service.
Alignment, quantification, integration and modelling are not part of a platform booking. They are run by GenXMap's R&D team, as the Claims Substantiation Package, a programme designed for your industry rather than a line on a quote. Ask for it in the quote request and both are scoped together.
Claims Substantiation Package at GenXMapHave a project in this space?